CA2645731A1 - N-substituted-azacyclylamines as histamine-3 antagonists - Google Patents

N-substituted-azacyclylamines as histamine-3 antagonists Download PDF

Info

Publication number
CA2645731A1
CA2645731A1 CA002645731A CA2645731A CA2645731A1 CA 2645731 A1 CA2645731 A1 CA 2645731A1 CA 002645731 A CA002645731 A CA 002645731A CA 2645731 A CA2645731 A CA 2645731A CA 2645731 A1 CA2645731 A1 CA 2645731A1
Authority
CA
Canada
Prior art keywords
methyl
benzimidazol
benzoyl
bipyrrolidine
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002645731A
Other languages
English (en)
French (fr)
Inventor
Derek Cecil Cole
Magda Asselin
Joseph Raymond Stock
Albert Jean Robichaud
Ji-In Kim
William Ronald Solvibile Jr.
Jonathan Laird Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2645731A1 publication Critical patent/CA2645731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002645731A 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists Abandoned CA2645731A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78251306P 2006-03-15 2006-03-15
US60/782,513 2006-03-15
US85907906P 2006-11-15 2006-11-15
US60/859,079 2006-11-15
PCT/US2007/005776 WO2007108936A2 (en) 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
CA2645731A1 true CA2645731A1 (en) 2007-09-27

Family

ID=38353957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002645731A Abandoned CA2645731A1 (en) 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists

Country Status (11)

Country Link
US (1) US7820825B2 (enExample)
EP (1) EP1994022A2 (enExample)
JP (1) JP2009530274A (enExample)
AR (1) AR059905A1 (enExample)
AU (1) AU2007227681A1 (enExample)
BR (1) BRPI0709612A2 (enExample)
CA (1) CA2645731A1 (enExample)
MX (1) MX2008011791A (enExample)
PE (1) PE20071023A1 (enExample)
TW (1) TW200800958A (enExample)
WO (1) WO2007108936A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
PE20080371A1 (es) 2006-05-19 2008-04-09 Wyeth Corp N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3
MX339668B (es) 2006-05-30 2016-06-02 Janssen Pharmaceutica N V * Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
EP2038269A1 (en) * 2006-06-29 2009-03-25 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine h3 receptor
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US20080293771A1 (en) * 2007-05-24 2008-11-27 Wyeth Azacyclylbenzamide derivatives as histamine-3 antagonists
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
CA2706328C (en) 2007-11-20 2016-04-19 Janssen Pharmaceutica N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
PL2445899T3 (pl) * 2009-06-26 2017-08-31 Sanofi Nowe sole fumaranowe antagonisty receptora histaminy H3
CA2825134A1 (en) 2011-01-25 2012-08-02 Kissei Pharmaceutical Co., Ltd. Indole derivative, and pharmacologically acceptable salt thereof
MY173845A (en) 2012-07-17 2020-02-24 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
US10106501B2 (en) 2015-06-09 2018-10-23 Abbvie Inc. Nuclear receptor modulators
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
JPH05507469A (ja) 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
CA2136999C (en) 1993-04-07 2004-05-11 Takafumi Fujioka Peripheral vasodilating agent containing piperidine derivative as active ingredient
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
AU7270798A (en) 1997-05-01 1998-11-24 Eli Lilly And Company Antithrombotic agents
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
AU2001247906A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles and indazoles
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
SI1603917T1 (sl) 2003-03-14 2011-04-29 Medigene Ag Imunomodulacijske heterociklične spojine
CA2561628C (en) * 2004-04-01 2012-05-08 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
HRP20080120T5 (hr) 2004-05-14 2012-07-31 Millennium@Pharmaceuticals Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
CN1989115B (zh) 2004-07-26 2012-03-21 伊莱利利公司 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途
EP1784400B1 (en) 2004-08-23 2015-01-14 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2006028269A2 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CA2595157A1 (en) 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US7566735B2 (en) 2006-03-20 2009-07-28 Glaxo Group Limited Compounds which potentiate AMPA receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20080371A1 (es) * 2006-05-19 2008-04-09 Wyeth Corp N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
AR059905A1 (es) 2008-05-07
MX2008011791A (es) 2008-09-25
WO2007108936A3 (en) 2007-11-01
AU2007227681A1 (en) 2007-09-27
US7820825B2 (en) 2010-10-26
JP2009530274A (ja) 2009-08-27
US20070219240A1 (en) 2007-09-20
BRPI0709612A2 (pt) 2011-07-19
WO2007108936A2 (en) 2007-09-27
PE20071023A1 (es) 2007-10-03
EP1994022A2 (en) 2008-11-26
TW200800958A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
US7820825B2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
EP0666858B1 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists
EP2074088A2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A2 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CN101356174B (zh) 吲哚-3-基-羰基-螺-哌啶衍生物
JP4927079B2 (ja) V1a受容体アンタゴニストとしてのインドール−3−イル−カルボニル−スピロ−ピペリジン誘導体
AU2005254658A1 (en) Indole derivatives as histamine receptor antagonists
AU2008256803A1 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
CA2751402A1 (en) Substituted indole compounds as bradykinin receptor 1 modulators
CN101547923A (zh) 作为via受体拮抗剂的螺环-哌啶衍生物
CN101426778A (zh) 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
EP3986885B1 (en) Substituted pyrrolidine amides iv
CN101679276A (zh) 用作nk3拮抗剂的异喹啉酮衍生物
AU2009315761A1 (en) Quinazoline derivatives as NK3 receptor antagonists
JP2010090067A (ja) 含窒素複素環誘導体
CN101277945A (zh) 吲哚-3-基-羰基-哌啶和哌嗪衍生物
HK1142068A (en) Isoquinolinone derivatives as nk3 antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130308